IL2 and metastatic melanoma: For instance, high clinical response rates have been obtained in metastatic melanoma patients with TIL-based protocols in combination with non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine) immediately prior or added to infusion of TIL and high-dose IL-2 therapy [11], [13].